Abstract 3167: Serum Activin A Level Is Associated With Infarct Size In Patients With Acute Myocardial Infarction Who Undergo Successful Primary Percutaneous Coronary Intervention
PURPOSE: Activin A, a member of the transforming growth factor-beta cytokine family, has been suggested to play a role in inflammation and have pleiotropic functions. We examined the alteration of serum activin A level in patients with ST-segment elevation myocardial infarction (STEMI) who received successful primary percutaneous coronary intervention (PCI) within 12 hours, and investigated whether serum activin A was associated with infarct size.
METHODS: We examined 26 patients with STEMI, 20 consecutive stable angina pectoris (AP) patients and 20 normal subjects. In STEMI patients, blood samples were collected before PCI (day0) and days 1, 2, 7 and 14. Serum activin A level was measured by enzyme-linked immunoassay. Change of activin A between day 2 and day0 (delta 2d) was also examined. The serum levels of activin A were compared with infarct size, as indicated with peak CK.
RESULTS: Patients with STEMI demonstrated significantly higher serum activin A level (before PCI) than control subjects and patients with AP (316±112, 369±153 and 569±272 pg/ml, p<0.001 and p=0.007, respectively). The activin A level was significantly elevated and peaked on day 0 and reduced on days 2, and then gradually increased until days 14. Log-transformed peak CK was significantly correlated with serum activin A level on day0 (r=0.55, p=0.004) and delta 2d (r=0.58, p=0.023). In stepwise analysis, serum activin A level (beta=0.37, p=0.022) as well as age, culprit lesion (LAD) and smoking was an independent predictor of peak CK.
CONCLUSIONS: The findings suggest that serum activin A level was elevated in STEMI and it may be associated with infarct size in STEMI patients.